Mushroom-Derived Compounds as Metabolic Modulators in Cancer

Bhoomika Dowaraka-Persad1,2, Vidushi Shradha Neergheen1

  • 1Biopharmaceutical Unit, Centre for Biomedical and Biomaterials Research (CBBR), University of Mauritius, Réduit 80837, Mauritius.

Insights

Mushroom compounds offer a natural approach to combat cancer by targeting metabolic reprogramming. These natural products show promise in selectively inhibiting cancer cell growth and halting proliferation.

Area of Science:

  • Biochemistry
  • Oncology
  • Pharmacology

Background:

  • Cancer significantly impacts quality of life, with metabolic alterations in carbohydrates, lipids, and proteins being key drivers.
  • Existing cancer drugs face limitations in systemic toxicity and pharmacokinetics, necessitating the search for safer, multi-targeted therapies.
  • Mushrooms have a history in ethnomedicine and cancer care, with their compounds demonstrating anti-cancer properties in preclinical studies.

Purpose of the Study:

  • To review how mushroom-derived metabolites can target metabolic reprogramming biomarkers in cancer.
  • To explore the potential of natural compounds from mushrooms as a therapeutic strategy against cancer.
  • To highlight selective anti-cancer mechanisms of mushroom compounds on metabolic pathways.

Main Methods:

  • Literature review of studies on mushroom-derived compounds and their effects on cancer metabolism.
  • Analysis of in vitro and in vivo studies demonstrating the anti-cancer activities of specific mushroom metabolites.
  • Examination of identified molecular targets and pathways affected by these compounds.

Main Results:

  • Panepoxydone demonstrated protective effects against breast cancer by modulating lactate dehydrogenase A and B, leading to apoptosis.
  • Neoalbaconol selectively induced cytotoxicity in nasopharyngeal carcinoma by inhibiting hexokinase 2.
  • GL22 inhibited hepatic tumor growth by downregulating fatty acid-binding proteins and affecting fatty acid transport and cardiolipin biosynthesis.

Conclusions:

  • Mushroom metabolites represent a promising source of novel anti-cancer agents targeting key metabolic pathways.
  • Targeting metabolic reprogramming offers a selective approach to halting cancer cell proliferation with potentially reduced toxicity.
  • Further research into mushroom-derived compounds could lead to new adjunct therapies for oncological care.

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
5.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K